Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab

BACKGROUND: We previously reported that in patients with HER2‐positive (HER2+) locally advanced breast cancer treated with neoadjuvant trastuzumab‐containing regimens, high HER2 to centromere enumerator probe 17 ratio on fluorescence in situ hybridization (HER2 FISH ratio) was an independent predict...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncologist
Κύριοι συγγραφείς: Kogawa, Takahiro, Fujii, Takeo, Wu, Jimin, Harano, Kenichi, Fouad, Tamer M., Liu, Diane D., Shen, Yu, Masuda, Hiroko, Krishnamurthy, Savitri, Chavez‐MacGregor, Mariana, Lim, Bora, Murthy, Rashmi K., Valero, Vicente, Tripathy, Debu, Ueno, Naoto T.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley & Sons, Inc. 2020
Θέματα:
Breast Cancer
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288623/
https://ncbi.nlm.nih.gov/pubmed/32003919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0611
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια